GleamWall
中文EN

LGND LIGAND PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 886163 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1.0%
TTM net income YoY5.9%
TTM EPS YoY9.7%
Revenue 3-yr CAGR18.2%
Net income 3-yr CAGR46.2%

Margins

Gross margin—
Operating margin9.5%
Net margin20.3%
FCF margin35.7%
EBITDA margin23.2%

Returns

ROE5.4%
ROA2.8%
ROIC (approx.)1.4%
Asset turnover0.14x

Leverage & solvency

Liabilities / assets57.0%
Debt / equity1.17x
Current ratio1.22x
Interest coverage2.94x

Cash quality & payout

Operating cash flow / net income1.77x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$268.09M$167.13M
R&D expense$81.18M$21.43M
SG&A expense$92.45M$78.65M
Operating income$41.00M-$22.61M
Interest expense$4.71M$3.04M
Pretax income$158.96M$2.52M
Income tax$34.51M$6.55M
Net income$124.45M-$4.03M
EBITDA$74.78M$12.63M
EPS (basic)6.44-0.22
EPS (diluted)6.13-0.22
Weighted avg. shares (diluted)20.29M18.29M
Balance sheet
Cash & equivalents$174.93M$72.31M
Short-term investments$558.59M$183.86M
Receivables$59.60M$38.38M
Inventory$9.13M$14.11M
Current assets$832.27M$331.56M
PP&E, net$3.57M$15.13M
Goodwill$101.54M$105.25M
Intangibles$225.44M$266.65M
Total assets$1.56B$941.77M
Current liabilities$37.45M$37.11M
Long-term debt$446.19M$0
Total debt$446.19M$0
Total liabilities$543.42M$111.33M
Shareholders' equity$1.02B$830.44M
Net debt$271.26M-$72.31M
Shares outstanding19.77M19.11M
Cash flow statement
Operating cash flow$49.36M$97.05M
Capital expenditure$452,000$1.82M
Free cash flow$48.91M$95.23M
Investing cash flow-$377.32M-$143.66M
Financing cash flow$428.22M$97.14M
Depreciation & amortization$33.77M$35.24M
Stock-based compensation$46.85M$41.09M
Share buybacks$15.00M$0

Free plan shows the latest 2 periods; Pro shows all 18 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.